{"classes":[{"categories":[{"measurements":[{"comment":"Geometric CV could not be calculated as only 1 participant was available for analysis.","groupId":"OG000","spread":"NA","value":"1926.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Area under the observed concentration-time curve from the time of dosing to Day 7 calculated by log-linear trapezoidal approximation.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received SEA-BCMA 1600 mg IV q2wk on Day 1 and 15 of each 28-day cycle, dexamethasone 40 mg orally or as an IV infusion on Day 1, 8, 15, and 22 and pomalidomide 4 mg orally, daily from Day 1 to 21 of each of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG000","title":"Part D: SEA-BCMA 1600 mg, Pomalidomide and Dexamethasone"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All treated participants analysis set included all treated participants who received any amount of SEA-BCMA. Here \"Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1: Pre dose, 1 and 2 hour intradose, end of drug administration, 2, 6 , 24, 72, and 168 hours post end of infusion on Day 1","title":"AUC0-7 of SEA-BCMA: Part D","type":"SECONDARY","unitOfMeasure":"Day*ug/mL"}